Compare GKOS & SCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GKOS | SCI |
|---|---|---|
| Founded | 1998 | 1962 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Other Consumer Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9B | 11.6B |
| IPO Year | 2015 | 1994 |
| Metric | GKOS | SCI |
|---|---|---|
| Price | $177.33 | $82.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 4 |
| Target Price | ★ $126.92 | $98.00 |
| AVG Volume (30 Days) | 580.7K | ★ 662.2K |
| Earning Date | 04-29-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 1.57% |
| EPS Growth | N/A | ★ 7.65 |
| EPS | N/A | ★ 1.87 |
| Revenue | $507,442,000.00 | ★ $4,309,234,000.00 |
| Revenue This Year | $23.32 | $4.03 |
| Revenue Next Year | $27.43 | $3.73 |
| P/E Ratio | ★ N/A | $44.25 |
| Revenue Growth | ★ 32.33 | 2.93 |
| 52 Week Low | $73.16 | $68.41 |
| 52 Week High | $191.62 | $90.99 |
| Indicator | GKOS | SCI |
|---|---|---|
| Relative Strength Index (RSI) | 55.85 | 50.40 |
| Support Level | $175.04 | $82.33 |
| Resistance Level | $184.00 | $83.37 |
| Average True Range (ATR) | 5.63 | 1.49 |
| MACD | -1.97 | -0.43 |
| Stochastic Oscillator | 30.42 | 36.99 |
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Service Corp International is a personal services company that provides funeral and cemetery services and products from its locations throughout the United States and Canada. The company segments its operations into funeral service and cemetery business functions. At its funeral service locations, it provides all professional services, facilities, vehicles, and merchandise related to funerals and cremations. Cemetery locations provide cemetery property, memorial markers, and graveyard services to customers. The company derives the majority of its revenue from its funeral services segment. Geographically, the company derives a majority of its revenue from the United States.